Title : Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Pub. Date : 2014 May 10

PMID : 24711549






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 HER2-HER3 signaling can be inactivated by doses of lapatinib that fully inactivate the HER2 kinase. Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens